Documents | Rituximab for the first-line treatment of chronic lymphocytic leukaemia | Guidance | NICE

Documents

A list of downloadable documents created during development.

Background information

Leukaemia (chronic lymphocytic, first line) - rituximab: review decision - March 2014 information
Appendix B: GE decision paper - March 2014 ^{PDF 110.09 KB} 08 April 2014
Leukaemia (chronic lymphocytic, first line) - rituximab: Review Proposal - January 2014 information
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix A - provisional matrix of stakeholders ^{PDF 100.52 KB} 20 January 2014
Leukaemia (chronic lymphocytic, first line) - rituximab: Appendix B proposal paper presented to the Institute's Guidance Executive ^{PDF 446.11 KB} 20 January 2014
Leukaemia (chronic lymphocytic, first line) - rituximab: review update - October 2012 information
Leukaemia (chronic lymphocytic, relapsed) - rituximab: review update - December 2010 information
NICE issues final guidance on the use of rituximab for first line chronic lymphocytic leukaemia ^{PDF 36.72 KB} 06 December 2013

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination

Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination information
Leukaemia (chronic lymphocytic, first line) - rituximab: final appraisal determination ^{PDF 137.94 KB} 15 June 2009
Response to consultee, commentator and public comments on the ACD and comments from website consultation ^{PDF 120.08 KB} 15 June 2009
Consultee and commentator comments on the ACD
Chronic Lymphocytic Leukaemia Support Association ^{PDF 19.99 KB} 15 June 2009
Department of Health ^{PDF 12.85 KB} 15 June 2009
Leukaemia CARE ^{PDF 13.28 KB} 15 June 2009
Roche ^{PDF 99.73 KB} 15 June 2009
Royal College of Nursing ^{PDF 18.71 KB} 15 June 2009
Royal College of Pathologists ^{PDF 8.32 KB} 15 June 2009
Comments from website consultation ^{PDF 20.11 KB} 15 June 2009

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation

Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation
Leukaemia (chronic lymphocytic, first line) - rituximab: appraisal consultation document information
Leukaemia (chronic lymphocytic, first line) - rituximab: evaluation report
Pre-meeting briefing ^{PDF 114.83 KB} 26 March 2009
Leukaemia (chronic lymphocytic, first line) - rituximab: evidence review group report ^{PDF 3.61 MB} 26 March 2009
Non-manufacturer submissions
Chronic Lymphocytic Leukaemia Support ^{PDF 49.31 KB} 26 March 2009
Hampshire PCT ^{PDF 24.26 KB} 26 March 2009
Royal College of Nursing ^{PDF 26.65 KB} 26 March 2009
Royal College of Physicians, Medical Oncology Joint Special Committee (on behalf of the NCRI/RCP/RCR/ACP/JCCO) ^{PDF 89.35 KB} 26 March 2009
UK CLL Forum ^{PDF 27.16 KB} 26 March 2009
UK CLL Forum, Royal College of Pathologists & British Society for Haematology ^{PDF 40.5 KB} 26 March 2009
Expert written personal statements
Barnard ^{PDF 97.11 KB} 26 March 2009
Milligan ^{PDF 14.03 KB} 26 March 2009
Pettitt ^{PDF 19.32 KB} 26 March 2009
Williams Durkin ^{PDF 41.49 KB} 26 March 2009
Manufacturer submission
Roche submission ^{PDF 4.22 MB} 26 March 2009
Manufacturer response to clarification letter ^{PDF 308.73 KB} 26 March 2009
Manufacturer response to supplementary clarification letter ^{PDF 18.33 KB} 26 March 2009
NICE clarification letter ^{PDF 35.33 KB} 26 March 2009
NICE supplementary clarification letter ^{PDF 16.08 KB} 26 March 2009
Utility Measurement Study for Patients with Chronic Lymphocytic Leukaemia: Interim Report ^{PDF 165.38 KB} 26 March 2009

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope (updated following CHMP positive opinion)

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope ^{PDF 27.49 KB} 24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope

Leukaemia (chronic lymphocytic, first line) - rituximab: final scope ^{PDF 27.49 KB} 24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: final matrix of consultees and commentators ^{PDF 47.26 KB} 24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the draft scope ^{PDF 73.56 KB} 24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix

Leukaemia (chronic lymphocytic, first line) - rituximab: comments on the provisional matrix ^{PDF 23.31 KB} 24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope

Leukaemia (chronic lymphocytic, first line) - rituximab: draft scope ^{PDF 30.59 KB} 24 September 2008

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators

Leukaemia (chronic lymphocytic, first line) - rituximab: provisional matrix of consultees and commentators ^{PDF 47.8 KB} 24 September 2008